Table 2.
Clinical and imaging characteristics of the study population (n=47)
| Baseline | Age (years) | 57.3±11.8 |
|
| ||
| Male sex | 78.7% (37/47) | |
|
| ||
| Risk factors | ||
| Atrial fibrillation | 14.9% (7/47) | |
| TIA before stroke | 10.6% (5/47) | |
| Hypertension | 46.8% (22/47) | |
| Diabetes | 6.4% (3/47) | |
| Hyperlipidemia | 12.8% (6/47) | |
|
| ||
| Onset-to-MRI time (min) | 256.5±97.8 | |
|
| ||
| NIHSS | 6 (3, 11) | |
|
| ||
| PVS | ||
| Extensive | 63.8% (30/47) | |
| Non-extensive | 36.2% (17/47) | |
| Cases with PCV only | 31.9% (15/47) | |
| Cases with both PCV and PMV | 68.1% (32/47) | |
| PVS-DWI mismatch | 97.9% (46/47) | |
|
| ||
| SVS positive | 59.6% (28/47) | |
|
| ||
| SVS length (mm) | 15.0±6.5 | |
|
| ||
| ICA/MCA | ||
| Intracranial ICA TIMI 0 | 12.8% (6/47) | |
| M1 segment TIMI 0 | 57.5% (27/47) | |
| M1 segment TIMI 1 | 10.6% (5/47) | |
| M1 segment TIMI 2 | 10.6% (5/47) | |
| M1 segment TIMI 3 | 4.3% (2/47) | |
| M2 segment TIMI 0 | 4.3% (2/47) | |
|
| ||
| Volume 1 (mL) | 6.2 (1.9, 24.3) | |
|
| ||
| Treatment | ||
| Intravenous thrombolysis | 34.0% (16/47) | |
| Endovascular treatment | 17.0% (8/47) | |
| Routine treatment | 48.9% (23/47) | |
|
| ||
| 7-day follow-up | NIHSS | 4 (1, 8)a |
|
| ||
| 7-day good outcome | 50.0% (23/46) | |
|
| ||
| Volume 2 (mL) | 31.3 (8.8, 67.6)b | |
|
| ||
| Infarct growth (mL) | 15.0 (1.7, 36.6)b | |
|
| ||
| ICA/MCA TIMI 2–3 | 66.0% (31/47) | |
|
| ||
| HT (PH1+PH2) | 21.7% (10/46) | |
Data are presented as mean ± standard deviation, median (interquartile range), or percentage (number/total).
TIA, transient ischemic attack; MRI, magnetic resonance imaging; NIHSS, National Institutes of Health Stroke Scale; PVS, prominent vessel sign; PCV, prominent cortical veins; PMV, prominent medullary veins; DWI, diffusion-weighted imaging; SVS, susceptibility vessel sign; ICA, internal carotid artery; MCA, middle cerebral artery; TIMI, thrombolysis in myocardial infarction; HT, hemorrhagic transformation; PH1, parenchymal hematoma type 1; PH2, parenchymal hematoma type 2.
a
Analyses were performed in 45 patients;
b
Analyses were performed in 46 patients.